Introduction
Targeting the renin-angiotensin system (RAS) is one of the most common therapeutic approaches in cardiovascular medicine. 1 The traditional concept of pharmacological RAS interference consists of prevention of excessive AT1-receptor stimulation by repression of synthesis of angiotensin II (Ang II) through inhibition of renin or angiotensin-converting enzyme (ACE) or by direct blockade of the AT1-receptor. This strategy is without a doubt a success story in cardiovascular therapy as documented by numerous clinical studies which reported reduced mortality and morbidity in treated patients. 2, 3 In recent years other receptors of the RAS such as the AT2-receptor and Mas, the function of which has long been rather enigmatic, have been better characterised in terms of signalling and physiological function, revealing the existence of a so-called "alternative" or "protective" RAS. Receptors of this arm of the RAS mediate tissueprotective actions counteracting the AT1-receptor but also counteracting cytokines, growth factors and proapoptotic stimuli. Stimulation of the AT2-receptor or Mas has been shown in multiple experimental models to ameliorate the course not only of cardiovascular, but also of renal, immunological and neurological diseases. 4, 5 Thus, AT2-receptors and Mas are nowadays regarded as future drug targets, and respective agonists are in various phases of drug development.
This article reviews new therapeutic pathways aiming either at inhibiting the deleterious Ang II/AT1 axis or at stimulating the protective ACE2/Mas/AT2 arm.
AT1-receptor blockers

New AT1-receptor blockers
The eight currently approved AT1-receptor blockers (ARBs) are well-established drugs for the treatment of hypertension, heart failure and kidney disease. The last addition to this armamentarium, azilsartan, which was approved in 2011, seems to be one of the most potent ARBs in terms of its antihypertensive efficacy, which may be due to its high affinity and slow dissociation from the AT1-receptor and its inverse agonistic properties. 6 However, data on long-term protection from end-organ damage are still to be awaited.
Biased AT1-receptor blockade
A very novel development in the field of ARBs is the concept of "biased" AT1-receptor blockade. Biased ARBs block AT1-receptor-coupled G-protein signalling in the "traditional" way, while simultaneously stimulating β-arrestin-coupled signalling which, for example, results in improved cardiac function. TRV120027 is the first biased ARB in clinical development and is currently being evaluated in a phase II clinical study for the treatment of heart failure. 7, 8 
AT1-receptor blockade combined with neutral endopeptidase inhibition
Modern approaches to increase the effectiveness of ARBs consist of their combination with other mechanisms of action. One such example is LCZ696, which is currently being developed by Novartis and combines valsartan with an inhibitor of neutral endopeptidase (NEP). 9 NEP is responsible for the degradation of atrial and brain natriuretic factor, which both have cardioprotective properties. Consequently, inhibition of NEP increases plasma levels of these protective molecules. LCZ696, which may become the first in class ARNI (AT1-receptor and NEP inhibitor) lowered blood-pressure more effectively than valsartan monotherapy in a phase II clinical trial. Phase III clinical trials are currently ongoing to test LCZ696 for the treatment of heart failure. Outcomes of these studies and data about long-term safety (potential risks for obesity, Alzheimer's disease and angioedema have been discussed) have to be awaited.
AT1-receptor blockade combined with endothelin A receptor blockade
RE-021 (formerly PS433540 or DARA) is a dual AT1-receptor and endothelin-A receptor (ETA) antagonist which was successfully taken through a phase IIb study in patients 
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AT1-receptor blockade combined with nitric oxide (NO) release
ARBs and ACE-inhibitors fused with NO-releasing entities have been developed by NicOx, but are now further developed by Merck. 11, 12 The status of development is unknown.
AT2-receptor agonists
For stimulation of the AT2-receptor, agonists are required which exhibit high receptor specificity to avoid concomitant stimulation of the AT1-receptor. For this reason, the natural ligand of the AT2-receptor, Ang II, is not a suitable candidate because it binds with almost equal affinity to the AT1-and the AT2-receptor and usually leads to predominance of AT1-receptor effects. The synthetic peptide CGP42112A, which had already been a key tool in the days of the original identification of AT2-receptors in 1989, fulfils the requirement of receptor specificity, but has never been considered to be developed into a drug for clinical use. This is probably owing to the fact that by the time of synthesis and patenting of CGP42112A, the physiological function of the AT2-receptor was widely unknown.
However, interest in the AT2-receptor has grown in recent years with the better characterisation of its favourable effects in disease models. This in turn has led to the initiation of new developmental programs for synthesis of new AT2-agonists.
One strategy to obtain AT2-receptor-specific ligands is the exchange of single amino acids within the Ang II molecule. This approach has originally been described by Miura and Karnik, exchanging single amino acids by alanine, which in most cases did not change nanomolar affinity of these angiotensin analogues to the AT2-receptor, but lowered affinity for the AT1-receptor thus making these ligands more specific for the AT2-receptor. 13 A similar approach has been performed by Rosenström et al. 14 and by Jones et al., 15 more recently exchanging amino acids by glycine or by beta-amino acids, respectively, which also mainly resulted in angiotensin analogues with higher AT2-receptor specificity. However, all of these Ang II-like peptides are not orally active and have only very limited plasma half-lives, which limits their clinical applicability. A very recent approach is trying to increase stability of an Ang II-like peptide (with one exchanged amino acid) by synthesising cyclic molecules. Such an AT2-agonist, named LP2, is currently in early preclinical development by Lanthio Pharma, Groningen, the Netherlands. 16 At present there is only one non-peptide, orally active AT2-receptor agonist, Compound 21 (formerly named M024), which was designed and synthesised in 2004 by the group of Mathias Alterman and Anders Hallberg at Uppsala University. 17 With a Ki of 0.4 nM for the AT2-receptor and ≥ 10.000 nM for the AT1-receptor, it displays high receptor specificity. Compound 21 (C21), which is owned by Vicore Pharma, 18 is currently undergoing extensive toxicological testing to comply with regulatory requirements and gain approval for a phase I clinical study in 2013.
It has not been finally decided about future clinical indications for AT2-receptor agonists. CGP42112A and C21 have been tested in a broad variety of preclinical models pointing to favourable therapeutic effects in cardiovascular (e.g. post-myocardial infarction (MI) cardiac function, hypertension-induced vascular remodelling, pulmonary hypertension), neurological (e.g. stroke, spinal cord injury, Alzheimer's disease) and immunological (e.g. multiple sclerosis, rheumatoid arthritis) diseases. 4, [19] [20] [21] Due to this broad spectrum of potential indications, the decision about a first clinical indication will be based on further parameters such as duration/size/costs of phase II and III studies and the putative future market situation.
Lanthio Pharma designates fibrosis and chronic neonatal lung disease as future indications for their cyclic AT2-agonist, but preclinical data of respective animal models are not yet available.
AT2-receptor antagonists
The AT2-receptor has been described as promoting neurite outgrowth. Since pathophysiology of neuropathic pain includes abnormal sprouting of neurite fibres in dorsal root ganglia, it has been suggested that antagonism of the AT2-receptor may be able to act antinociceptively in neuropathic pain. An orally active derivative of the well-known AT2-receptor antagonist PD123319, EMA401, is being developed by Spinifex Pharma for this indication and was recently shown to be effective in the treatment of post-herpetic pain in a phase II study. 22
Angiotensin 1-7, analogues and special formulations
In analogy to the AT2-receptor, the receptor Mas mediates tissue-protective actions and has been shown to have favourable, therapeutic effects in a broad spectrum of disease models such as hypertension, post-MI cardiac failure, metabolic syndrome, diabetes, renal disease and rheumatoid arthritis.
The natural ligand of Mas, angiotensin 1-7 (Ang 1-7), exhibits high selectivity and specificity for its receptor and can therefore be used as an agonist. However, Ang 1-7 again is a peptide and thus has a short plasma half-life and is rapidly degraded in the gastrointestinal tract when given orally. Thus, attempts to make Mas stimulation suitable for clinical use mainly concentrate on finding orally active formulations/derivatives of Ang (1-7) or at least increasing its plasma half-life.
HPβCD/Ang-(1-7)
A very straightforward approach for making Ang (1-7) orally active is to encapsulate the peptide molecule into particles which are not degraded in the stomach or small intestine, but only in the gut, which is the favoured site for peptide resorption. HPβCD/Ang-(1-7), which is Ang (1-7) encapsulated into a cyclodextrin, is the result of such an approach and has been shown to act cardioprotectively after MI and anti-thrombotically when applied orally. 23 
NorLeu 3 -angiotensin 1-7
NorLeu 3 -angiotensin 1-7 is a patented peptide analogue of Ang (1-7) which is currently developed as DSC127 for topic treatment of diabetic foot ulcers by Derma Sciences 24 and as TXA127 for improvement of stem cell engraftment by Tarix Pharmaceuticals. 25 Furthermore, TXA127 has orphan drug status for the treatment of pulmonary hypertension. Both DCS127 and TXA127 developments are in advanced stages, with TXA127 having completed phase I and DCS127 phase II testing. 26 
CGEN-856
CGEN-856 is a peptide Mas-agonist with no significant homology to Ang (1-7), which has been identified by a computational screen combined with a calcium flux assay. 27 In animal models CGEN-856 proved to be antihypertensive and anti-arrhythmic. 28 This molecule will now enter clinical development in a collaboration between Compugen 29 and BioLineRx. 30 
Cyclic angiotensin 1-7
Apart from synthesising a cyclic AT2-agonist based on the Ang II peptide, Lanthio Pharma has also generated a cyclic analogue of Ang (1-7), termed PanCyte, which is now being licensed to Tarix Pharmaceuticals, where it is intended to be developed for the treatment of serious pulmonary diseases. 25 
AVE-0991
AVE-0991 is an orally active, non-peptide Mas agonist synthesised by Hoechst/Aventis. 31 It has been shown in animal models to possess cardio-renal protective effects, acting in an antihypertensive, antihypertrophic, antifibrotic and antiatherosclerotic way. Despite this multitude of favourable experimental data, the development of AVE-0991 has been stopped by Hoechst/Aventis for unknown strategic reasons.
Recombinant ACE2 and ACE2 activators
Angiotensin-converting enzyme 2 (ACE2) is the enzyme responsible for cleavage of Ang (1-7) from Ang II or Ang I (via Ang (1-9) ). Thus increasing activity of ACE2 is an indirect way of increasing Ang (1-7) plasma levels and Mas stimulation. There are two general ways of gaining higher ACE2 activity: either increasing the amount of ACE2 by application of recombinant ACE2 or activation of existing ACE2.
Recombinant human ACE2
Recombinant human ACE2 (APN01) was synthesised and successfully taken through a phase I study by Apeiron Biologics. 32 It is now licensed to Glaxo-Smith-Kline and will soon enter a multi-centre phase IIa study in patients with acute lung injury.
ACE2 activators
A structure-based screening process revealed several compounds enhancing ACE2 activity, including the first lead compound XNT, which, however, turned out to have problematic pharmacokinetic properties. 33 Experimental studies are currently mainly performed with a United States Food and Drug Administration (FDA)-approved anti-protozoal drug, diminazine aceturate (DIZE). It is not known to the authors whether it is intended to use DIZE as an ACE2 activator clinically.
Conclusion
Although these days drugs targeting the RAS are already among the most commonly described in cardiovascular medicine, new developments are still on the way which in general target the RAS by two entirely diverse approaches: either they aim at inhibiting the renin-ACE-AT1-receptor axis, which is involved in the pathophysiology of a number of cardiovascular diseases, or they aim at potentiating Mas or AT2-receptor actions thus stimulating the protective RAS. While new developments targeting the renin-ACE-AT1-axis mainly consist of attempts to make existing drug classes more effective by new combinations (ARBs plus NEPs or NO-releasing entities or ETA-antagonists) or by refining the mechanism of action (biased ARBs), new developments targeting the protective RAS are all still in (pre-)clinical development and -if approved -will become first-in-class drugs. With respect to future indications, new drugs interfering with the renin-ACE-AT1-axis are all being developed for "classical", cardiovascular indications, in particular hypertension and heart failure. In contrast, the spectrum of indications suggested for future drugs interfering with the protective RAS is immensely broad and ranges from pulmonary hypertension, acute lung injury and chronic neonatal lung disease to improvement of stem cell engraftment, treatment of pain or even topical treatment of diabetic ulcers. It is of note that so far no "classical" cardiovascular indications are among those suggested for drugs targeting the protective RAS. Thus the emergence of these novel drugs may not only help to improve treatment of various diseases with an unmet therapeutic need, but it may further significantly broaden perception of the physiological actions and the therapeutic potential of the RAS.
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